Navigation Links
New and unique treatment for Psoriasis patients

Psoriasis patients who have been long-awaiting new options in treatment, now have fresh hope with the Food and Drug Administration's approval of the new drug, Amevive. This unique drug targets renegade immune cells to control hard-to-treat psoriasis. Psoriasis has been thought to occur when the immune system goes amok and cells called memory effector T cells prompt skin inflammation. The treatments that are currently available for psoriasis range from ointments to ultraviolet therapy to other injected drugs that can broadly suppress// the immune system. The new drug Amevive, however has been designed to target only the harmful T cells, instead of the entire immune system. Physicians have been eagerly awaiting the drug as it works differently from those drugs that are available in the market presently.

The drug, whose effect has not yet been compared with existing treatments, will be marketed in intravenous and intra-muscular injection forms. The treatment, for a 12-week course, will cost between $7000 and $10,000 and the weekly dose will be administered under the supervision of a doctor.

Biogen Inc., the makers of the drug, sponsored a study, which involved patients with chronic psoriasis that covered at least 10 percent of their bodies, and gave them either Amevive or dummy injections. They found that 40 per cent of patients on the Amevive drug saw their psoriasis symptoms cut in half, as compared to about 10 percent of placebo-treated patients. A small number of patients even saw their lesions almost vanish, for at least a while. Though the duration for which the effect lasted was not known, a small subset of patients went seven months or longer before needing additional treatment. The FDA's Dr. Karen Weiss cautioned that though the drug has a much more selective effect, it is still too soon to say it is very selective and very safe. In fact, she added that patients on the drug would require a blood test before each weekly dose to ensure the ir levels of infection-fighting immune cells have not dipped too low, which would require postponing a dose. Another theoretical concern is that by suppressing the immune system, the risk of cancer might increase. The FDA, while not restricting the number of times patients can repeat Amevive therapy when their psoriasis recurs, has warned that the effects of the drug on developing fetus is not yet known.


'"/>




Related medicine news :

1. A unique factor in breathing disorder
2. Pink Shawl Project is a unique initiative
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular ... violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his ... in violence in the United States. The study, Trends in Fighting and ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... Dudnyk ... new identity emphasizes the agency’s conviction that the full potential of specialty and orphan ... are equally appreciated and aligned. , “The Unifying Effect is at the heart ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets ... Pipeline and Market Prospects: Addressing Production Complexities Through Risk ... offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities ... in-depth assessment of the current trends in the global ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
Breaking Medicine Technology: